The evolving role of glycoprotein (GP) IIb/IIIa receptor blockade during percutaneous coronary intervention of saphenous vein bypass grafts.
D'Agate
David J
DJ
Department of Cardiology, Saint Vincent Catholic Medical Centers, New York, NY, 10011, USA.
Patel
Snehal
S
Coppola
John T
JT
Ambrose
John A
JA
D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D000925:Anticoagulants / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000473:pathology / Q000628:therapy; D023903:Coronary Restenosis / Q000517:prevention & control; D004617:Embolism / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012501:Saphenous Vein / Q000637:transplantation*; D016896:Treatment Outcome
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex